Freddie Mac Prices Multifamily Floating Rate K-Deal, K-F10

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Freddie Mac Prices Multifamily Floating Rate K-Deal, K-F10

MCLEAN, VA--(Marketwired - Oct 7, 2015) -   Freddie Mac ( OTCQB : FMCC ) recently priced a new offering of Structured Pass-Through Certificates ( K Certificates ), backed exclusively by floating rate multifamily mortgages with five- and seven-year terms. The approximately $1.3 billion in K Certificates (K-F10 Certificates) are expected to settle on or about October 23, 2015. This is the company's 20 th K Certificates offering this year.

 
K-F10 Pricing
 
Class   Principal/ Notional Amount (mm)   Weighted Average Life (Years)   Discounted Margin   Coupon   Yield   Dollar Price
A   $1,311.277   6.29   38   1 mo LIBOR + 38   0.5807%   100.00
X1   $1,456.975   2.44   Non-Offered
             

Details

  • Lead Manager: Merrill Lynch, Pierce, Fenner & Smith Incorporated
  • Co-Lead Manager: J.P. Morgan Securities LLC
  • Co-Managers: Barclays Capital Inc., CastleOak Securities, L.P. and Goldman, Sachs & Co.

Related Links

The K-F10 Certificates will not be rated, and include one senior principal and interest class and one senior interest only class. The K-F10 Certificates are backed by corresponding classes issued by the FREMF 2015-KF10 Mortgage Trust (K-F10 Trust) and guaranteed by Freddie Mac. The K-F10 Trust will also issue certificates consisting of the Class B and R Certificates, which will be subordinate to the classes backing the K-F10 Certificates. The K-F10 Trust Class B and R Certificates will not be guaranteed by Freddie Mac.

Freddie Mac Multifamily is a leading issuer of agency-guaranteed structured multifamily securities. K-Deals are part of the company's business strategy to transfer a portion of the risk of losses away from taxpayers and to private investors who purchase the unguaranteed subordinate bonds. K Certificates typically feature a wide range of investor options with stable cash flows and structured credit enhancement.

This announcement is not an offer to sell any Freddie Mac securities. Offers for any given security are made only through applicable offering circulars and related supplements, which incorporate Freddie Mac's Annual Report on Form 10-K for the year ended December 31, 2014, filed with the Securities and Exchange Commission (SEC) on February 19, 2015; all other reports Freddie Mac filed with the SEC pursuant to Section 13(a) of the Securities Exchange Act of 1934 (Exchange Act) since December 31, 2014, excluding any information "furnished" to the SEC on Form 8-K; and all documents that Freddie Mac files with the SEC pursuant to Sections 13(a), 13(c) or 14 of the Exchange Act, excluding any information furnished to the SEC on Form 8-K.

Freddie Mac's press releases sometimes contain forward-looking statements. A description of factors that could cause actual results to differ materially from the expectations expressed in these and other forward-looking statements can be found in the company's Annual Report on Form 10-K for the year ended December 31, 2014, and its reports on Form 10-Q and Form 8-K, filed with the SEC and available on the Investor Relations page of the company's Web site at www.FreddieMac.com/investors and the SEC's Web site at www.sec.gov .

Freddie Mac was established by Congress in 1970 to provide liquidity, stability and affordability to the nation's residential mortgage markets. Freddie Mac supports communities across the nation by providing mortgage capital to lenders. Today Freddie Mac is making home possible for one in four home borrowers and is one of the largest sources of financing for multifamily housing. Additional information is available at FreddieMac.com , Twitter @FreddieMac and Freddie Mac's blog FreddieMac.com/blog .

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 310

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 607

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 386

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 513

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 731

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 98

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 385

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 518

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 137

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 332

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
icles